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Background
Human CD317 (BST-2/HM1.24/tetherin) restricts the
release of multiple viruses including HIV-1, XMRV,
Lassa virus and KSHV from infected cells in culture. Its
relevance for infection control in humans is however
unclear, in part due to its poorly defined in vivo-expres-
sion pattern.
Materials and methods
To provide a framework for studies into the biological
functions, regulation and therapeutic potential of
CD317, we performed a tissue microarray-based expres-
sion profiling in 468 samples of 25 healthy organs from
over 250 patients, not suffering from clinically apparent
infections.
Results
We report that CD317 protein was expressed to varying
degrees in all organs tested and detected in a number of
specialized cell types including hepatocytes, pneumo-
cytes in the lung, ducts of major salivary glands, pan-
creas and kidney, Paneth cells in the small intestine,
epithelia of multiple organs, Leydig cells in the testis,
plasma cells, bone marrow stromal cells, monocytes, and
vascular endothelium. Remarkably, many of these
CD317-positive cell types are in vivo-targets for patho-
genic viruses, only for some of which restriction by
CD317 or virus-encoded antagonists have thus far been
investigated. Of note, major HIV target cells in tonsil
and gut-associated lymphoid tissue did not express
CD317. Limited, cell type-dependent co-expression of
CD317 with the interferon biomarker MxA in vivo and
an unresponsiveness to cytokine stimulation in lym-
phoid organ explants suggest that type I interferons may
only in part regulate CD317.
Conclusions
This in vivo-expression profiling sheds light on the biol-
ogy and species-specificity of CD317, identifies multiple
novel interaction sites of viruses with this restriction
factor, and refutes the widely-held belief of its restricted
constitutive expression and primary interferon inducibil-
ity. Work is in progress to define anatomical compart-
ments and/or pathological conditions under which
CD317 is expressed in HIV-1 target cells ex vivo and in
vivo.
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